<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02899728</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2016-01363</org_study_id>
    <secondary_id>NCI-2016-01363</secondary_id>
    <secondary_id>17-732</secondary_id>
    <secondary_id>s16-01472</secondary_id>
    <secondary_id>9974</secondary_id>
    <secondary_id>9974</secondary_id>
    <secondary_id>UM1CA186709</secondary_id>
    <nct_id>NCT02899728</nct_id>
  </id_info>
  <brief_title>Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy&#xD;
      work in treating patients with small cell lung cancer. Drugs used in chemotherapy, such as&#xD;
      carboplatin, cisplatin, and etoposide, work in different ways to stop the growth of tumor&#xD;
      cells, either by killing the cells, by stopping them from dividing, or by stopping them from&#xD;
      spreading. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some&#xD;
      of the enzymes needed for cell growth. Olaparib, cediranib maleate, and standard chemotherapy&#xD;
      may work better in treating patients with small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether the addition of cediranib maleate (cediranib) plus olaparib as&#xD;
      maintenance therapy, in patients with small cell lung cancer (SCLC) who have stable disease&#xD;
      or better (non-progressive disease or non-PD) after initial therapy, leads to improved median&#xD;
      progression-free survival (PFS), PFS is measured in months from the time of randomization to&#xD;
      maintenance therapy (after completion of initial therapy), compared to standard therapy (no&#xD;
      maintenance treatment.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the impact of cediranib plus olaparib maintenance therapy on median overall&#xD;
      survival (OS) in patients with SCLC who have non-PD after initial therapy.&#xD;
&#xD;
      II. To determine whether the addition of cediranib to cisplatin/carboplatin plus etoposide&#xD;
      during initial therapy adds benefit to response rate, median PFS and median OS.&#xD;
&#xD;
      III. To assess safety and tolerability of the combination of cediranib plus olaparib during&#xD;
      maintenance therapy.&#xD;
&#xD;
      IV. To evaluate potential biomarkers of clinical benefit to olaparib/cediranib combination,&#xD;
      including tumor proteomic and genomic markers, and circulating levels of cytokines and&#xD;
      angiogenic factors, that that may be associated with clinical benefit.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      INITIAL THERAPY PHASE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive carboplatin intravenously (IV) over 60 minutes or cisplatin IV over&#xD;
      60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats&#xD;
      every 21 days for up to 4 cycles in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      ARM II: Patients receive treatment as in Arm I and also receive cediranib maleate orally (PO)&#xD;
      once daily (QD) on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients in Arm I who have stable disease, partial, or a complete response are randomized to&#xD;
      receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to&#xD;
      receive maintenance therapy.&#xD;
&#xD;
      MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO twice daily&#xD;
      (BID) on days 1-28.&#xD;
&#xD;
      NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with&#xD;
      cediranib maleate and olaparib upon disease progression at the treating investigator's&#xD;
      discretion.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3-4 months for at least 1&#xD;
      year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inadequate accrual rate&#xD;
  </why_stopped>
  <start_date type="Actual">April 7, 2017</start_date>
  <completion_date type="Actual">March 17, 2020</completion_date>
  <primary_completion_date type="Actual">March 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Progression-free Survival in Patients Who Receive Cediranib Maleate/Olaparib as Maintenance Therapy</measure>
    <time_frame>From second randomization to documented disease progression or death from any cause, whichever occurs first, assessed up to 6 months</time_frame>
    <description>Will be compared to those receiving standard therapy. will use the intention-to-treat framework in which all patients randomized are considered recipients of their randomized assignment, regardless of treatment actually received.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) Rate</measure>
    <time_frame>From initial randomization to death from any cause, assessed up to 2 years</time_frame>
    <description>Additional sensitivity analyses will be conducted on OS to address the effect of potential crossover to olaparib/cediranib on overall survival estimates. These will include rank preserving structural failure time models.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Rates in each arm will be provided with exact 95% confidence intervals, and compared using the chi-squared test (or Fisher's exact test, as needed).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood-based Angiogenic and Deoxyribonucleic Acid (DNA) Repair Biomarkers</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Assessed by whole exome sequencing. Will be summarized using descriptive statistics.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of Genomic Aberrations</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Will be assessed using McNemar's test and Fisher's exact test. More sophisticated analyses may include multivariable logistic regression modeling and/or competing risks analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Circulating Free DNA</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>Will be analyzed for association with patient demographics and/or disease characteristics using the Kruskal Wallis test.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Extensive Stage Lung Small Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <other_name>Blastocarb</other_name>
    <other_name>Carboplat</other_name>
    <other_name>Carboplatin Hexal</other_name>
    <other_name>Carboplatino</other_name>
    <other_name>Carboplatinum</other_name>
    <other_name>Carbosin</other_name>
    <other_name>Carbosol</other_name>
    <other_name>Carbotec</other_name>
    <other_name>CBDCA</other_name>
    <other_name>Displata</other_name>
    <other_name>Ercar</other_name>
    <other_name>JM-8</other_name>
    <other_name>Nealorin</other_name>
    <other_name>Novoplatinum</other_name>
    <other_name>Paraplatin</other_name>
    <other_name>Paraplatin AQ</other_name>
    <other_name>Paraplatine</other_name>
    <other_name>Platinwas</other_name>
    <other_name>Ribocarbo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cediranib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <other_name>AZD2171</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cediranib Maleate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <other_name>AZD2171</other_name>
    <other_name>AZD2171 Maleate</other_name>
    <other_name>Recentin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <other_name>Abiplatin</other_name>
    <other_name>Blastolem</other_name>
    <other_name>Briplatin</other_name>
    <other_name>CDDP</other_name>
    <other_name>Cis-diammine-dichloroplatinum</other_name>
    <other_name>Cis-diamminedichloridoplatinum</other_name>
    <other_name>Cis-diamminedichloro Platinum (II)</other_name>
    <other_name>Cis-diamminedichloroplatinum</other_name>
    <other_name>Cis-dichloroammine Platinum (II)</other_name>
    <other_name>Cis-platinous Diamine Dichloride</other_name>
    <other_name>Cis-platinum</other_name>
    <other_name>Cis-platinum II</other_name>
    <other_name>Cis-platinum II Diamine Dichloride</other_name>
    <other_name>Cismaplat</other_name>
    <other_name>Cisplatina</other_name>
    <other_name>Cisplatinum</other_name>
    <other_name>Cisplatyl</other_name>
    <other_name>Citoplatino</other_name>
    <other_name>Citosin</other_name>
    <other_name>Cysplatyna</other_name>
    <other_name>DDP</other_name>
    <other_name>Lederplatin</other_name>
    <other_name>Metaplatin</other_name>
    <other_name>Neoplatin</other_name>
    <other_name>Peyrone''s Chloride</other_name>
    <other_name>Peyrone''s Salt</other_name>
    <other_name>Placis</other_name>
    <other_name>Plastistil</other_name>
    <other_name>Platamine</other_name>
    <other_name>Platiblastin</other_name>
    <other_name>Platiblastin-S</other_name>
    <other_name>Platinex</other_name>
    <other_name>Platinol</other_name>
    <other_name>Platinol- AQ</other_name>
    <other_name>Platinol-AQ</other_name>
    <other_name>Platinol-AQ VHA Plus</other_name>
    <other_name>Platinoxan</other_name>
    <other_name>Platinum</other_name>
    <other_name>Platinum Diamminodichloride</other_name>
    <other_name>Platiran</other_name>
    <other_name>Platistin</other_name>
    <other_name>Platosin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <other_name>Demethyl Epipodophyllotoxin Ethylidine Glucoside</other_name>
    <other_name>EPEG</other_name>
    <other_name>Lastet</other_name>
    <other_name>Toposar</other_name>
    <other_name>Vepesid</other_name>
    <other_name>VP 16</other_name>
    <other_name>VP 16-213</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
    <other_name>VP16</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <arm_group_label>Arm II (chemotherapy, cediranib maleate, olaparib)</arm_group_label>
    <other_name>AZD 2281</other_name>
    <other_name>AZD-2281</other_name>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
    <other_name>Lynparza</other_name>
    <other_name>PARP Inhibitor AZD2281</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of extensive-stage small cell lung&#xD;
             cancer with no prior systemic treatment&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded for&#xD;
             non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm (&gt;= 2 cm) with&#xD;
             conventional techniques or as &gt;= 10 mm (&gt;= 1 cm) with spiral computed tomography (CT)&#xD;
             scan, magnetic resonance imaging (MRI), or calipers by clinical exam&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  White blood cell count (WBC) &gt;= 3 x 10^9/L (within 28 days prior to administration of&#xD;
             therapy)&#xD;
&#xD;
          -  No features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)&#xD;
             on peripheral blood smear (within 28 days prior to administration of therapy)&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mcL (within 28 days prior to administration of&#xD;
             therapy)&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL (within 28 days prior to administration of therapy)&#xD;
&#xD;
          -  Hemoglobin &gt;= 10 g/dL with no blood transfusion within 28 days of initiation of&#xD;
             therapy (within 28 days prior to administration of therapy)&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN) (within 28 days&#xD;
             prior to administration of therapy)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase&#xD;
             (SGOT)/alanine aminotransferase (ALT) serum glutamate pyruvate transaminase (SGPT) =&lt;&#xD;
             2.5 x institutional ULN, unless liver metastases are present and then =&lt; 5 x&#xD;
             institutional ULN is acceptable (within 28 days prior to administration of therapy)&#xD;
&#xD;
          -  Creatinine clearance &gt;= 50 mL/min (within 28 days prior to administration of therapy)&#xD;
&#xD;
          -  Proteinuria - urine protein:creatinine ratio (UPC) of =&lt; 1 OR =&lt; 2+ proteinuria on two&#xD;
             consecutive urinalysis/dipstick tests taken no less than 1 week apart; patients with&#xD;
             2+ proteinuria on dipstick must also have a UPC of =&lt; 0.5 on 2 consecutive samples&#xD;
             (within 28 days prior to administration of therapy)&#xD;
&#xD;
          -  Ability to swallow and retain oral medication&#xD;
&#xD;
          -  The effects of olaparib and cediranib on the developing human fetus are unknown; for&#xD;
             this reason and because other therapeutic agents used in this trial are known to be&#xD;
             teratogenic, women of child-bearing potential and male patients and their partners who&#xD;
             are sexually active must agree to use two highly effective forms of contraception in&#xD;
             combination for the duration of study participation and for 3 months after completion&#xD;
             of olaparib and cediranib administration; should a woman become pregnant or suspect&#xD;
             she is pregnant while she or her partner is participating in this study, she should&#xD;
             inform her treating physician immediately&#xD;
&#xD;
          -  Postmenopausal or evidence of non-pregnant status for women of childbearing potential&#xD;
             as confirmed by a negative urine or serum pregnancy test within 7 days prior to the&#xD;
             start of therapy; postmenopausal status is defined as:&#xD;
&#xD;
               -  Age &gt;= 60 years, or&#xD;
&#xD;
               -  Age &lt; 60 with any one or more of the conditions below:&#xD;
&#xD;
                    -  Amenorrheic for &gt;= 1 year in the absence of chemotherapy and/or hormonal&#xD;
                       treatments,&#xD;
&#xD;
                    -  Luteinizing hormone and/or follicle stimulating hormone and/or estradiol&#xD;
                       levels in the post-menopausal range,&#xD;
&#xD;
                    -  Radiation-induced oophorectomy with last menses &gt; 1 year ago,&#xD;
&#xD;
                    -  Chemotherapy-induced menopause with &gt; 1 year interval since last menses,&#xD;
&#xD;
                    -  Surgical sterilization (bilateral oophorectomy or hysterectomy)&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Participants must have archival tumor tissue available for analysis (minimum 20 5 um&#xD;
             slide) or be able to undergo a baseline fresh tumor tissue biopsy&#xD;
&#xD;
          -  Adequately controlled blood pressure; (defined as systolic blood pressure [SBP] of =&lt;&#xD;
             140 mmHg and diastolic blood pressure [DBP] of =&lt; 90 mmHg) on maximum of three&#xD;
             antihypertensive medications; participants must have a blood pressure (BP) of =&lt;&#xD;
             140/90 taken in the clinic or hospital setting by a medical professional within 2&#xD;
             weeks prior to starting on study; it is strongly recommended that participants who are&#xD;
             on 3 antihypertensive medications be followed by a cardiologist or a primary care&#xD;
             physician for management of BP while on study&#xD;
&#xD;
          -  Adequately controlled thyroid function, with no symptoms of thyroid dysfunction;&#xD;
             patients can be on thyroid hormone replacement medication; asymptomatic patients with&#xD;
             elevated thyroid stimulating hormone (TSH) with normal T4/T3 are allowed to enroll,&#xD;
             and recommended to follow with routine thyroid function test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had major surgery or trauma within 28 days prior to entering the&#xD;
             study; patients must have recovered from any effects of any major surgery and surgical&#xD;
             wound should have healed prior to starting treatment&#xD;
&#xD;
          -  Patients who have had radiotherapy within 14 days prior to entering the study&#xD;
&#xD;
          -  Patients with a non-healing wound, fracture, or ulcer&#xD;
&#xD;
          -  Patients who have not recovered from adverse events due to prior anti-cancer therapy&#xD;
             (i.e., have residual toxicities &gt; Common Terminology Criteria for Adverse Events&#xD;
             [CTCAE] grade 1 or baseline, with the exception of alopecia)&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  Patients with symptomatic central nervous system (CNS) metastases or leptomeningeal&#xD;
             carcinomatosis should be excluded from this clinical trial because of their poor&#xD;
             prognosis and because they often develop progressive neurologic dysfunction that would&#xD;
             confound the evaluation of neurologic and other adverse events; exceptions include&#xD;
             patients with previously-treated CNS metastases or those with are asymptomatic,&#xD;
             subcentimeter metastases, and have no requirement for steroids or anti-seizure&#xD;
             medication for at least one week prior to study entry; screening with CNS imaging&#xD;
             studies (CT scan or MRI) is required&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to olaparib, cediranib, carboplatin, cisplatin, or etoposide&#xD;
&#xD;
          -  Patients with a history of myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  Patients with a history of acute myeloid leukemia (AML), or patients with a history of&#xD;
             any other primary malignancy within 3 years prior to initiation of treatment on this&#xD;
             study; exceptions include: patients with a history of malignancies (other than AML)&#xD;
             that were treated curatively and have not recurred within 3 years prior to study&#xD;
             entry; resected basal and squamous cell carcinomas of the skin; and completely&#xD;
             resected carcinoma in situ of any type&#xD;
&#xD;
          -  Patients with clinically significant gastrointestinal abnormalities including, but not&#xD;
             limited to:&#xD;
&#xD;
               -  Clinically significant signs and/or symptoms of bowel obstruction within 3 months&#xD;
                  prior to starting treatment&#xD;
&#xD;
               -  History of intra-abdominal abscess within 3 months prior to starting treatment&#xD;
&#xD;
               -  History of gastrointestinal (GI) perforation within 6 months prior to starting&#xD;
                  treatment&#xD;
&#xD;
               -  Evidence of abdominal fistula within 6 months prior to starting treatment;&#xD;
                  history of abdominal fistula will be considered eligible if the fistula was&#xD;
                  surgically repaired, and there has been no evidence of fistula for at least 6&#xD;
                  months prior to starting treatment, and patient is deemed to be at low risk of&#xD;
                  recurrent fistula&#xD;
&#xD;
          -  Patients with a history of cerebrovascular accident including transient ischemic&#xD;
             attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis&#xD;
             (DVT) within the past 3 months; Note: Participants with recent DVT who have been&#xD;
             treated with therapeutic anti-coagulants for at least 6 weeks are eligible, with the&#xD;
             exception of participants being treated with warfarin, which is prohibited on this&#xD;
             study; other oral anti-coagulants may be allowed after discussion with overall&#xD;
             principal investigator (PI), but short half-life low molecular weight heparins are&#xD;
             strongly preferred&#xD;
&#xD;
          -  Patients with evidence of active bleeding diathesis&#xD;
&#xD;
          -  Patients with hemoptysis in excess of 2.5 mL within 6 weeks prior to the first dose of&#xD;
             study medication&#xD;
&#xD;
          -  Patients receiving any medications or substances that are potent inhibitors or&#xD;
             inducers of CYP3A4 are ineligible; the required washout period for strong inhibitors&#xD;
             is 2 weeks and at least one week for moderate inhibitors; the required washout period&#xD;
             prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 4 weeks&#xD;
             for other agents&#xD;
&#xD;
          -  Patients requiring concomitant therapy with phenytoin, phenobarbital, carbamazepine,&#xD;
             or valproic acid&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements; specifically, patients with any of the following within 6 months&#xD;
             prior to starting treatment are excluded:&#xD;
&#xD;
               -  Acute myocardial infarction&#xD;
&#xD;
               -  Unstable angina&#xD;
&#xD;
               -  New York Heart Association functional classification of III or IV&#xD;
&#xD;
               -  Left ventricular ejection fraction (LVEF) &lt; lower limit of normal (LLN) per&#xD;
                  institutional guidelines, or 55%&#xD;
&#xD;
               -  Prior allogeneic bone marrow transplant or double umbilical cord blood&#xD;
                  transplantation&#xD;
&#xD;
               -  Patients with active hepatitis (B or C)&#xD;
&#xD;
               -  Patients with active pneumonitis&#xD;
&#xD;
          -  Pregnant women are excluded from this study because olaparib and cediranib are agents&#xD;
             with the potential for teratogenic or abortifacient effects; because there is an&#xD;
             unknown but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with olaparib or cediranib, breastfeeding should be&#xD;
             discontinued if the mother is treated with olaparib or cediranib; these potential&#xD;
             risks may also apply to other agents used in this study&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral&#xD;
             therapy are ineligible because of the potential for pharmacokinetic interactions with&#xD;
             olaparib and cediranib; in addition, these patients are at increased risk of lethal&#xD;
             infections when treated with marrow-suppressive therapy; appropriate studies will be&#xD;
             undertaken in patients receiving combination antiretroviral therapy when indicated&#xD;
&#xD;
          -  Patients must be willing and able to check and record daily blood pressure readings if&#xD;
             receiving cediranib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Sands</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber - Harvard Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Los Angeles County-USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC / Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Medical Center of USC Pasadena</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224-9980</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at West County Hospital</name>
      <address>
        <city>Creve Coeur</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Christian Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Saint Peters Hospital</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63376</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 13, 2016</study_first_submitted>
  <study_first_submitted_qc>September 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <results_first_submitted>March 22, 2021</results_first_submitted>
  <results_first_submitted_qc>March 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2021</results_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Small Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Podophyllotoxin</mesh_term>
    <mesh_term>Cediranib</mesh_term>
    <mesh_term>Poly(ADP-ribose) Polymerase Inhibitors</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02899728/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Chemotherapy, Cediranib Maleate, Olaparib)</title>
          <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Chemotherapy, Cediranib Maleate, Olaparib)</title>
          <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5">0</participants>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Chemotherapy, Cediranib Maleate, Olaparib)</title>
          <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Chemotherapy, Cediranib Maleate, Olaparib)</title>
          <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="3"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median Progression-free Survival in Patients Who Receive Cediranib Maleate/Olaparib as Maintenance Therapy</title>
        <description>Will be compared to those receiving standard therapy. will use the intention-to-treat framework in which all patients randomized are considered recipients of their randomized assignment, regardless of treatment actually received.</description>
        <time_frame>From second randomization to documented disease progression or death from any cause, whichever occurs first, assessed up to 6 months</time_frame>
        <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Median Progression-free Survival in Patients Who Receive Cediranib Maleate/Olaparib as Maintenance Therapy</title>
          <description>Will be compared to those receiving standard therapy. will use the intention-to-treat framework in which all patients randomized are considered recipients of their randomized assignment, regardless of treatment actually received.</description>
          <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) Rate</title>
        <description>Additional sensitivity analyses will be conducted on OS to address the effect of potential crossover to olaparib/cediranib on overall survival estimates. These will include rank preserving structural failure time models.</description>
        <time_frame>From initial randomization to death from any cause, assessed up to 2 years</time_frame>
        <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) Rate</title>
          <description>Additional sensitivity analyses will be conducted on OS to address the effect of potential crossover to olaparib/cediranib on overall survival estimates. These will include rank preserving structural failure time models.</description>
          <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events</title>
        <description>Assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events</title>
          <description>Assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.</description>
          <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate</title>
        <description>Rates in each arm will be provided with exact 95% confidence intervals, and compared using the chi-squared test (or Fisher's exact test, as needed).</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Chemotherapy, Cediranib Maleate, Olaparib)</title>
            <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate</title>
          <description>Rates in each arm will be provided with exact 95% confidence intervals, and compared using the chi-squared test (or Fisher's exact test, as needed).</description>
          <population>Zero participants were analyzed because this trial was closed administratively per CTEP.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Blood-based Angiogenic and Deoxyribonucleic Acid (DNA) Repair Biomarkers</title>
        <description>Assessed by whole exome sequencing. Will be summarized using descriptive statistics.</description>
        <time_frame>Up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Frequency of Genomic Aberrations</title>
        <description>Will be assessed using McNemar's test and Fisher's exact test. More sophisticated analyses may include multivariable logistic regression modeling and/or competing risks analysis.</description>
        <time_frame>Baseline up to 2 years</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Circulating Free DNA</title>
        <description>Will be analyzed for association with patient demographics and/or disease characteristics using the Kruskal Wallis test.</description>
        <time_frame>Baseline up to 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Chemotherapy, Cediranib Maleate, Olaparib)</title>
          <description>Patients receive carboplatin IV over 60 minutes or cisplatin IV over 60 minutes on day 1 and etoposide IV over 60 minutes on days 1, 2, and 3. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
Patients in Arm I who have stable disease, partial, or a complete response are randomized to receive maintenance therapy or no maintenance therapy. Patients in Arm II are assigned to receive maintenance therapy.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
NO MAINTENANCE THERAPY: Patients are eligible to crossover to receive treatment with cediranib maleate and olaparib upon disease progression at the treating investigator's discretion.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Chemotherapy, Cediranib Maleate, Olaparib)</title>
          <description>Patients receive treatment as in Arm I and also receive cediranib maleate PO QD on days 1-21. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.&#xD;
MAINTENANCE THERAPY: Patients receive cediranib maleate PO QD and olaparib PO BID on days 1-28.&#xD;
Carboplatin: Given IV&#xD;
Cediranib: Given PO&#xD;
Cediranib Maleate: Given PO&#xD;
Cisplatin: Given IV&#xD;
Etoposide: Given IV&#xD;
Olaparib: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jacob Sands, MD</name_or_title>
      <organization>Dana- Farber Cancer Institute</organization>
      <phone>617-632-6049</phone>
      <email>Jacob_Sands@DFCI.HARVARD.EDU</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

